Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
University of Maryland, Baltimore
Study ID
NCT06993597
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Prostaglandin Analogue -Containing IOP-Lowering Therapy — DRUG
    Subjects with glaucoma may be prescribed prostaglandin analogs as part of their clinical care. This group will be observed longitudinally to assess changes in corneal biomechanics.
  • Beta Blocker — DRUG
    Subjects with glaucoma may be prescribed topical beta blockers as part of their clinical care. This group will be observed longitudinally to assess changes in corneal biomechanics.
  • Brillouin Microscopy — DEVICE
    Brillouin microscopy is a non-contact optical imaging method used to assess the biomechanical properties of the cornea in vivo with three-dimensional resolution. It will be used to evaluate corneal stiffness in all study subjects.

Study Details

This pilot study evaluates the biomechanical properties of the cornea in glaucoma patients using Brillouin microscopy, a non-contact imaging technique. The study aims to compare corneal stiffness between patients with normal-tension glaucoma, high-tension glaucoma, and healthy controls, and to assess changes in corneal biomechanics following intraocular pressure (IOP)-lowering treatment. The goal is to determine whether Brillouin-derived biomechanical measurements can serve as biomarkers for glaucoma risk and progression.

Key Dates

Start date
Sep 1, 2025
Status verified
Sep 2025
Primary completion
Mar 31, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Normal Tension Glaucoma
    Newly diagnosed, treatment-naïve subjects with normal tension glaucoma. Brillouin imaging will be performed at baseline, and in a subset receiving IOP-lowering therapy, additional imaging will be performed at 3 and 6 weeks.
  • Arm: High Tension Glaucoma
    Newly diagnosed, treatment-naïve subjects with high tension glaucoma. Brillouin imaging will be performed at baseline, and in a subset receiving IOP-lowering therapy, additional imaging will be performed at 3 and 6 weeks.
  • Arm: Control
    Age-matched healthy control subjects with no history of glaucoma or IOP-lowering therapy. Brillouin imaging will be performed at a single time point for cross-sectional comparison.

Primary Outcome Measure

Change in Corneal Biomechanical Modulus [ Time Frame: Baseline, 3 weeks, and 6 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Maryland School of MedicineBaltimoreMaryland21201-1757
Osamah Saeedi, MD
[email protected]
667-214-1232
[email protected]
Osamah Saeedi, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Baltimore, MD

By condition
Glaucoma
By specialty
Ophthalmology
By research site
University of Maryland School of Medicine· Baltimore, MD

Related Studies